Peptide therapy basics on TikTok: separating fact from hype

What did @patriciaunedited actually say?

Patricia's video is a sourcing and education primer for peptide beginners. She outlines three ways to obtain peptides: telehealth prescriptions, compounding pharmacies, and research-grade suppliers. She's transparent that she uses the third option herself and that research-grade products are sold "not for human consumption." She frames the whole thing as a personal journey, not professional guidance, and repeatedly tells viewers to educate themselves before touching anything.

She also lists the questions beginners should be asking: dosage, mechanism of action, reconstitution, syringe selection. The tone is earnest and community-oriented. She's not selling anything in the video itself, though she does mention links in her bio pointing to research-grade suppliers.

Does the science back this up?

Her general framework, that peptides require serious pre-use education, is well-supported. The science here is actually her weakest area though, because she relies almost entirely on community learning rather than peer-reviewed literature, which is a real limitation worth naming.

The claim that compounding pharmacies and telehealth represent "regulated" routes is partially accurate but needs unpacking. Compounding pharmacies operate under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act and are subject to state pharmacy board oversight and, for 503B facilities, FDA inspection. That is meaningful regulation. However, the peptides themselves often lack FDA-approved drug status, which creates a legal gray zone that Patricia glosses over. A 2023 FDA guidance update specifically addressed the status of peptides like BPC-157 and TB-500 as bulk drug substances, raising questions about whether compounding them is even permitted under current rules (FDA, 2023, Bulk Drug Substances Under Section 503A).

Research-grade suppliers operate outside FDA oversight for human use. Full stop. The COA and third-party testing she recommends are better than nothing, but they do not substitute for Good Manufacturing Practice standards required for pharmaceutical-grade products.

What did they get right (or wrong)?

Credit where it's due: the instruction to verify certificates of analysis and third-party testing before buying from a research supplier is genuinely useful harm-reduction advice. That's more than most beginner peptide content offers.

She gets the regulatory framing mostly right on compounding but understates the current legal uncertainty. Calling compounding pharmacies "very regulated" is accurate in isolation but misleading in context, because the peptides themselves may not be legal to compound. That nuance matters.

The bigger issue is the bio links. She directs an 8,600-person audience to research-grade suppliers with a "not for human consumption" label, then explains exactly how to use those products on humans. That's a legal and safety problem no amount of educational framing fully resolves. Saying "not medical advice" does not change the practical effect of the content.

Her sourcing of education, PubMed, Google Scholar, TikTok doctors, peptide courses from personal training platforms, is uneven. PubMed is legitimate. A GLP-1 course from a personal training certification platform is not a substitute for clinical pharmacology training, and treating them as equivalent credentials is a stretch.

What should you actually know?

If you're considering peptides, the regulatory picture is more complicated than this video suggests. The FDA has moved to restrict certain peptides from compounding. In October 2023, the FDA finalized a list of bulk drug substances that may not be used in compounding, and several peptides commonly discussed in communities like this one are under active review or restriction. Checking the current FDA 503A bulks list before assuming a compounding route is available is not optional; it's necessary.

Research-grade peptides present real contamination and dosing risks. A 2021 analysis of research-chemical suppliers (Cohen et al., 2021, JAMA Internal Medicine) found significant purity and labeling inconsistencies across unregulated online suppliers. A COA from the same company selling the product is not independent verification.

Telehealth providers who legitimately prescribe peptides should be conducting clinical intake, reviewing labs, and documenting medical necessity. If a platform skips those steps, that's a red flag, not a feature.